特刊“糖尿病肾病：诊断、预防与治疗”。
Special Issue "Diabetic Nephropathy: Diagnosis, Prevention and Treatment".
作者信息
Ruiz-Ortega Marta, Rodrigues-Diez Raul R, Lavoz Carolina, Rayego-Mateos Sandra
机构信息
Molecular and Cellular Biology in Renal and Vascular Pathology, IIS-Fundación Jiménez Díaz-UniversidadAutónoma Madrid, 28040 Madrid, Spain.
Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, 28029 Madrid, Spain.
出版信息
J Clin Med. 2020 Mar 17;9(3):813. doi: 10.3390/jcm9030813.
Abstract
Diabetic nephropathy (DN) is the main cause of end-stage renal disease. DN is a complex disease mediated by genetic and environmental factors, and many cellular and molecular mechanisms are involved in renal damage in diabetes. There are no biomarkers that reflect the severity of the underlying renal histopathological changes and can effectively predict the progression of renal damage and stratify the risk of DN among individuals with diabetes mellitus. Current therapeutic strategies are based on the strict control of glucose and blood pressure levels and, although there are new anti-diabetic drugs, these treatments only retard renal damage progression, being necessary novel therapies. In this Special Issue, there are several comprehensive reviews and interesting original papers covering all these topics, which would be of interest to the growing number of readers of the .
摘要
糖尿病肾病（DN）是终末期肾病的主要病因。DN是一种由遗传和环境因素介导的复杂疾病，糖尿病患者肾脏损伤涉及多种细胞和分子机制。目前尚无能够反映潜在肾脏组织病理学变化严重程度、有效预测肾脏损伤进展以及对糖尿病患者的DN风险进行分层的生物标志物。当前的治疗策略基于严格控制血糖和血压水平，尽管有新型抗糖尿病药物，但这些治疗仅能延缓肾脏损伤进展，因此需要新的治疗方法。在本期特刊中，有几篇涵盖所有这些主题的全面综述和有趣的原创论文，这将吸引越来越多的《》读者。
相似文献
1
Special Issue "Diabetic Nephropathy: Diagnosis, Prevention and Treatment".特刊“糖尿病肾病：诊断、预防与治疗”。
J Clin Med. 2020 Mar 17;9(3):813. doi: 10.3390/jcm9030813.
2
Prevalence and Management of Diabetic Nephropathy in Western Countries.西方国家糖尿病肾病的患病率及管理。
Kidney Dis (Basel). 2015 May;1(1):61-70. doi: 10.1159/000382028. Epub 2015 May 1.
3
The Prevalence and Management of Diabetic Nephropathy in Asia.亚洲地区糖尿病肾病的患病率和管理。
Kidney Dis (Basel). 2015 May;1(1):52-60. doi: 10.1159/000381757. Epub 2015 Apr 30.
4
Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy.糖尿病肾病的病理生理学和临床方面的新见解。
Rev Endocr Metab Disord. 2017 Mar;18(1):21-28. doi: 10.1007/s11154-017-9422-3.
5
Management of diabetic nephropathy: Recent progress and future perspective.糖尿病肾病的管理：近期进展与未来展望
Diabetes Metab Syndr. 2015 Oct-Dec;9(4):343-58. doi: 10.1016/j.dsx.2015.02.008. Epub 2015 Mar 6.
6
Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.从年轻1型糖尿病患者糖尿病肾病自然史研究中吸取的经验教训。
Pediatr Endocrinol Rev. 2008 Aug;5 Suppl 4:958-63.
7
Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective.糖尿病肾病的机制洞察与管理：近期进展与未来展望
J Diabetes Res. 2017;2017:1839809. doi: 10.1155/2017/1839809. Epub 2017 Mar 13.
8
The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases.分析糖尿病肾病进展的危险因素，并构建慢性肾脏病预后数据库。
J Transl Med. 2019 Aug 13;17(1):264. doi: 10.1186/s12967-019-2016-y.
9
New therapeutic agents in diabetic nephropathy.糖尿病肾病的新型治疗药物。
Korean J Intern Med. 2017 Jan;32(1):11-25. doi: 10.3904/kjim.2016.174. Epub 2017 Jan 1.
10
Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy.白细胞介素-17A 阻断可减少糖尿病肾病加速模型中的蛋白尿和肾脏损伤。
Kidney Int. 2019 Jun;95(6):1418-1432. doi: 10.1016/j.kint.2018.12.031. Epub 2019 Mar 8.
引用本文的文献
1
Relationship between serum irisin levels and renal function in patients with type 2 diabetes mellitus.2型糖尿病患者血清鸢尾素水平与肾功能的关系
Caspian J Intern Med. 2025 Jun 23;16(3):493-499. doi: 10.22088/cjim.16.3.493. eCollection 2025 Summer.
2
Targeting programmed cell death pathways: emerging therapeutic strategies for diabetic kidney disease.靶向程序性细胞死亡途径：糖尿病肾病的新兴治疗策略
Front Endocrinol (Lausanne). 2025 Jun 11;16:1513895. doi: 10.3389/fendo.2025.1513895. eCollection 2025.
3
The effect of Zuogui-Jiangtang-Yishen decoction on the intestinal flora's response to L-α-phosphatidylcholine and L-tyrosine in patients with diabetic kidney disease: an study.左归丸加味降糖益肾方对糖尿病肾病患者肠道菌群对L-α-磷脂酰胆碱和L-酪氨酸反应的影响：一项研究
Front Pharmacol. 2025 Jun 11;16:1573514. doi: 10.3389/fphar.2025.1573514. eCollection 2025.
4
Cross-country inequalities in the epidemiology of chronic kidney disease due to type 2 diabetes mellitus, 1990-2021: findings from the global burden of disease study 2021.1990 - 2021年2型糖尿病所致慢性肾脏病流行病学的跨国不平等：全球疾病负担研究2021的结果
Diabetol Metab Syndr. 2025 Jun 23;17(1):240. doi: 10.1186/s13098-025-01824-3.
5
Association between physiological serum total bilirubin concentrations and the progression of diabetic nephropathy.生理血清总胆红素浓度与糖尿病肾病进展之间的关联。
Front Endocrinol (Lausanne). 2025 May 29;16:1588568. doi: 10.3389/fendo.2025.1588568. eCollection 2025.
6
Association of Left Atrium Remodeling With Major Adverse Cardiovascular Events in Asymptomatic Type 2 Diabetes Patients With Early Chronic Kidney Disease.无症状2型糖尿病合并早期慢性肾脏病患者左心房重构与主要不良心血管事件的关联
Rev Cardiovasc Med. 2025 May 21;26(5):27247. doi: 10.31083/RCM27247. eCollection 2025 May.
7
Elucidating the function of clusterin in the progression of diabetic kidney disease.阐明簇集素在糖尿病肾病进展中的作用。
Front Pharmacol. 2025 May 14;16:1573654. doi: 10.3389/fphar.2025.1573654. eCollection 2025.
8
Comparison of artificial intelligence-generated and physician-generated patient education materials on early diabetic kidney disease.人工智能生成与医生生成的早期糖尿病肾病患者教育材料的比较
Front Endocrinol (Lausanne). 2025 Apr 22;16:1559265. doi: 10.3389/fendo.2025.1559265. eCollection 2025.
9
The Identification of Biomarkers and Therapeutic Targets for Diabetic Kidney Disease by Integrating the Proteome with the Genome.通过整合蛋白质组与基因组鉴定糖尿病肾病的生物标志物和治疗靶点
Biomedicines. 2025 Apr 16;13(4):971. doi: 10.3390/biomedicines13040971.
10
Role of gasdermins in chronic kidney disease.Gasdermin蛋白在慢性肾脏病中的作用。
Front Immunol. 2025 Apr 1;16:1557707. doi: 10.3389/fimmu.2025.1557707. eCollection 2025.
本文引用的文献
1
Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients.尿E-钙黏蛋白：糖尿病患者肾损伤早期检测的标志物。
J Clin Med. 2020 Feb 27;9(3):639. doi: 10.3390/jcm9030639.
2
Gla-Rich Protein (GRP) as an Early and Novel Marker of Vascular Calcification and Kidney Dysfunction in Diabetic Patients with CKD: A Pilot Cross-Sectional Study.富含γ-羧基谷氨酸蛋白（GRP）作为糖尿病合并慢性肾脏病患者血管钙化和肾功能不全的早期新型标志物：一项横断面初步研究
J Clin Med. 2020 Feb 27;9(3):635. doi: 10.3390/jcm9030635.
3
Matrix Metalloproteinases in Diabetic Kidney Disease.糖尿病肾病中的基质金属蛋白酶
J Clin Med. 2020 Feb 8;9(2):472. doi: 10.3390/jcm9020472.
4
Inflammatory Targets in Diabetic Nephropathy.糖尿病肾病中的炎症靶点
J Clin Med. 2020 Feb 7;9(2):458. doi: 10.3390/jcm9020458.
5
The Coming Age of Flavonoids in the Treatment of Diabetic Complications.黄酮类化合物治疗糖尿病并发症的崭新时代
J Clin Med. 2020 Jan 27;9(2):346. doi: 10.3390/jcm9020346.
6
VEGFR2 Blockade Improves Renal Damage in an Experimental Model of Type 2 Diabetic Nephropathy.血管内皮生长因子受体2阻断可改善2型糖尿病肾病实验模型中的肾损伤。
J Clin Med. 2020 Jan 21;9(2):302. doi: 10.3390/jcm9020302.
7
Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?白细胞介素-17A能否成为糖尿病肾病的新型治疗靶点？
J Clin Med. 2020 Jan 19;9(1):272. doi: 10.3390/jcm9010272.
8
The Error of Estimated GFR in Type 2 Diabetes Mellitus.2型糖尿病中估算肾小球滤过率的误差
J Clin Med. 2019 Sep 26;8(10):1543. doi: 10.3390/jcm8101543.
9
Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study.β2肾上腺素能受体激动剂与糖尿病患者血管并发症风险的关联：一项基于人群的队列研究。
J Clin Med. 2019 Jul 31;8(8):1145. doi: 10.3390/jcm8081145.
10
Therapeutic Potential of to Prevent Methylglyoxal-Induced Glucotoxicity in Familiar Diabetic Nephropathy.预防甲基乙二醛诱导的家族性糖尿病肾病糖毒性的治疗潜力。
J Clin Med. 2019 Jul 31;8(8):1138. doi: 10.3390/jcm8081138.
Zotero 插件